...
首页> 外文期刊>Annals of Clinical Microbiology and Antimicrobials >Molecular detection of blaCTX-M gene to predict phenotypic cephalosporin resistance and clinical outcome of Escherichia coli bloodstream infections in Vietnam
【24h】

Molecular detection of blaCTX-M gene to predict phenotypic cephalosporin resistance and clinical outcome of Escherichia coli bloodstream infections in Vietnam

机译:Blactx-M基因的分子检测预测越南大肠杆菌血流感染表型头孢菌素抗性及临床结局

获取原文
           

摘要

Blood stream infections (BSI) caused by Extended Spectrum Beta-Lactamases (ESBLs) producing Enterobacteriaceae is a clinical challenge leading to high mortality, especially in developing countries. In this study, we sought to describe the epidemiology of ESBL-producing Escherichia coli strains isolated from Vietnamese individuals with BSI, to investigate the concordance of genotypic-phenotypic resistance, and clinical outcome of ESBL E. coli BSI. A total of 459 hospitalized patients with BSI were screened between October 2014 and May 2016. 115 E. coli strains from 115 BSI patients were isolated and tested for antibiotic resistance using the VITEK?2 system. The ESBL phenotype was determined by double disk diffusion method following the guideline of Clinical and Laboratory Standards Institute. Screening for beta-lactamase (ESBL and carbapenemase) genes was performed using a multiplex-PCR assay. 58% (67/115) of the E. coli strains were ESBL-producers and all were susceptible to both imipenem and meropenem. Resistance to third-generation cephalosporin was common, 70% (81/115) were cefotaxime-resistant and 45% (52/115) were ceftazidime-resistant. blaCTX-M was the most common ESBL gene detected (70%; 80/115) The sensitivity and specificity of blaCTX-M-detection to predict the ESBL phenotype was 87% (76–93% 95% CI) and 54% (39–48% 95% CI), respectively. 28%% (22/80) of blaCTX-M were classified as non-ESBL producers by phenotypic testing for ESBL production. The detection of blaCTX-M in ESBL-negative E. coli BSI was associated with fatal clinical outcome (27%; 6/22 versus 8%; 2/26, p?=?0.07). A high prevalence of ESBL-producing E. coli isolates harbouring blaCTX-M was observed in BSI patients in Vietnam. The genotypic detection of blaCTX-M may have added benefit in optimizing and guiding empirical antibiotic therapy of E. coli BSI to improve clinical outcome.
机译:由扩展谱β-内酰胺酶(ESBLS)引起的血流感染(BSI)产生肠杆菌菌造成的临床攻击是导致高死亡率的临床攻击,特别是在发展中国家。在这项研究中,我们试图描述从BSI中越南人分离的ESBL生产大肠杆菌菌株的流行病学,以研究基因型 - 表型抗性的一致性,以及ESBL大肠杆菌BSI的临床结果。 2014年10月和2016年5月之间共有459名与BSI患者进行了筛选。115大肠杆菌菌株从115例BSI患者分离,并使用Vitekα进行抗生素抗性进行抗生素抗性。在临床和实验室标准研究所的指导下,通过双盘扩散法测定ESBL表型。使用多重PCR测定法进行β-内酰胺酶(ESBL和碳碱酶)基因的筛选。 58%(67/115)的大肠杆菌菌株是ESBL-生产者,所有人都易于伊皮脂和梅洛涅姆。耐血孢菌素常见,70%(81/115)是头孢噻肟抗性,45%(52/115)是头孢他啶的抗性。 Blactx-M是检测到的最常见的ESBL基因(70%; 80/115)Blactx-M检测的敏感性和特异性预测ESBL表型为87%(76-93%95%CI)和54%(39分别为-48%95%CI)。 28 %%(22/80)的Blactx-M通过对ESBL生产的表型测试进行分类为非ESBL生产商。在ESBL阴性大肠杆菌BSI中检测Blactx-M与致命临床结果有关(27%; 6/22与8%; 2/26,P?= 0.07)。在越南的BSI患者中观察到Esbl-生产E. Coli分离物的高患病率。 Blactx-M的基因型检测可能在优化和引导大肠杆菌BSI的经验抗生素治疗方面增加了益处,以改善临床结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号